News
FDA approves larotrectinib for cancers with NTRK gene fusions
Larotrectinib is approved for patients with solid tumors that have progressed following treatment and harbor a NTRK gene fusion without a...
News
TKIs and immunotherapy hold promise for alveolar soft part sarcoma
Tyrosine kinase inhibitors and immune checkpoint inhibitors show encouraging results in the treatment of alveolar soft part sarcoma
Conference Coverage
Predicting treatment response in leiomyosarcoma, liposarcoma
Aberrations in oncogenic pathways and immune modulation influence treatment response in patients with metastatic leiomyosarcoma or liposarcoma.
Conference Coverage
SEAL: Selinexor extends PFS in advanced dedifferentiated liposarcoma
The statistical significance of the improvements varied depending on how progression-free survival was measured.
News
Chromoplexy linked to aggressive Ewing sarcomas
Analysis of the sequence context surrounding chromoplexy breaks may provide clues and potentially point to a therapeutic vulnerability that could...
News
FDA lifts partial hold on tazemetostat trials
The partial hold that paused U.S.-based enrollment in clinical trials of tazemetostat has been lifted.
Education Center
Improved survival in liposarcoma
News
PARP inhibitor plus trabectedin shows promise for sarcoma
Investigators planning phase 2 studies after phase 1b results demonstrated tolerability and efficacy with the combination of olaparib and...
Journal Club
Novel molecular assay: Promising results in bone and soft tissue tumor evaluation
Two new fusion partners for the USP6 gene were found using AMP-based targeted next-generation sequencing.
Conference Coverage
Lurbinectedin shows activity against relapsed Ewing’s
CHICAGO – The agent blocks DNA transcription and induces double-strand breaks leading to apoptosis; results warrant further exploration,...
Conference Coverage
Adjuvant chemotherapy benefits high-risk sarcoma patients
Chemotherapy halved the risk of disease progression and death for patients with low probability of 10-year overall survival.
Conference Coverage
Rapid drug alteration a bust in metastatic GIST
Short alternating cycles of sunitinib with regorafenib failed to reach active drug levels in patients with heavily pretreated disease.
Conference Coverage
ctDNA profiles pre- and posttreatment KIT mutations in GIST
CHICAGO – A broad spectrum KIT inhibitor should be a part of post-imatinib therapy for GIST, data from a phase 1 study suggest.
Conference Coverage
Novel TKI PLX9486 showed efficacy against KIT mutations in GIST
CHICAGO – Combined with another investigational tyrosine kinase inhibitor, the compound showed activity against a broad range of resistance...
Conference Coverage
Low response rate with trofosfamide for advanced STS in elderly
CHICAGO – Of 80 patients with previously untreated metastatic soft-tissue sarcomas, 2 had complete, durable responses to oral trofosfamide.